atrasentan has been researched along with Neoplasms in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (71.43) | 29.6817 |
2010's | 2 (28.57) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aubert, JD; Juillerat-Jeanneret, L | 1 |
Bazan, V; Bronte, G; Di Gaudio, F; Fanale, D; Gebbia, N; Rizzo, S; Russo, A | 1 |
Bagnato, A; Battistini, B; Nelson, J; Nisen, P | 1 |
Garber, K | 1 |
André, AK; Carr, RA; Humerickhouse, R; Kindler, HL; Ratain, MJ; Ryan, CW; Undevia, SD; Vogelzang, NJ; Vokes, EE; Wang, Q | 1 |
Choueiri, TK; Garcia, JA; Thakkar, SG | 1 |
Lalich, M; Liu, G; McNeel, DG; Wilding, G | 1 |
4 review(s) available for atrasentan and Neoplasms
Article | Year |
---|---|
Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.
Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Endothelin Receptor Antagonists; Fibrosis; Humans; Hypertension, Pulmonary; Neoplasms; Receptors, Endothelin | 2016 |
Anti-endothelin drugs in solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Drug Delivery Systems; Drugs, Investigational; Endothelin Receptor Antagonists; Endothelins; Humans; Male; Models, Biological; Neoplasms; Prostatic Neoplasms; Pyrrolidines; Receptors, Endothelin; Signal Transduction | 2010 |
The endothelin axis: emerging role in cancer.
Topics: Amino Acid Sequence; Antineoplastic Agents; Atrasentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelins; Humans; Male; Neoplasms; Prostatic Neoplasms; Protein Conformation; Pyrrolidines; Receptor, Endothelin A; Receptors, Endothelin | 2003 |
Endothelin receptor antagonists in cancer therapy.
Topics: Atrasentan; Bosentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Female; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Pyrimidines; Pyrrolidines; Receptors, Endothelin; Signal Transduction; Sulfonamides | 2007 |
1 trial(s) available for atrasentan and Neoplasms
Article | Year |
---|---|
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Atrasentan; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasms; Prostatic Neoplasms; Pyrrolidines; Receptors, Endothelin; Sex Factors; Time Factors | 2004 |
2 other study(ies) available for atrasentan and Neoplasms
Article | Year |
---|---|
Why it hurts: researchers seek mechanisms of cancer pain.
Topics: Acidosis; Analgesics; Animals; Antineoplastic Agents; Atrasentan; Bone Neoplasms; Diphosphonates; Disease Models, Animal; Glycoproteins; Humans; Ion Channels; Neoplasms; Osteoprotegerin; Pain; Pyrrolidines; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor | 2003 |
Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.
Topics: Antineoplastic Agents; Atrasentan; Clinical Trials as Topic; Disease Progression; Endothelin A Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Humans; Male; Neoplasms; Prostatic Neoplasms; Pyrrolidines; Receptor, Endothelin A; Receptors, Endothelin | 2006 |